文献速递鼻科

优化难治性慢性鼻窦炎伴鼻息肉患者的生物制剂与手术治疗时机

Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP).
PubMed 文献 · Int Forum Allergy Rhinol · 2023-08-10

回顾性病例对照研究比较生物制剂治疗期间接受内镜鼻窦手术与仅用生物制剂的难治性慢性鼻窦炎伴鼻息肉患者。随访12个月,联合手术组总鼻息肉评分从4.73降至0.09,仅生物制剂组从5.22降至3.38,组间差异显著(95%CI -5.37至-1.38,p=0.005)。作者认为联合治疗可显著且持续降低息肉负荷,但需更大规模研究进一步验证。

要点

  • 生物制剂治疗期间联合内镜鼻窦手术,12个月总鼻息肉评分降至0.09,优于仅用生物制剂组。
  • 联合组与对照组基线特征(适应证、SNOT-22、息肉评分、AERD状态)无显著差异。
  • 作者结论认为联合治疗可显著持续降低息肉负荷,但需更大规模研究进一步验证。

核心结论

  • 在难治性慢性鼻窦炎伴鼻息肉患者中,内镜鼻窦手术联合生物制剂治疗相比仅用生物制剂可显著且持续降低息肉负荷。
  • 作者认为需要更大规模的研究来进一步检验联合治疗的影响。

研究设计与样本

  • 回顾性病例对照研究,比较生物制剂治疗期间接受内镜鼻窦手术的慢性鼻窦炎伴鼻息肉患者(联合组)与仅接受生物制剂治疗的患者(对照组)。
  • 联合组16例(13例使用度普利尤单抗,3例使用美泊利单抗),对照组16例;两组按适应证、阿司匹林加重性呼吸系统疾病、SNOT-22评分和总息肉评分进行匹配。

主要发现

  • 两组在适应证、基线SNOT-22评分、息肉评分和AERD状态方面无显著差异。
  • 联合组在开始生物制剂治疗后中位33天接受手术。
  • 随访12个月,联合组总息肉评分从4.73降至0.09,对照组从5.22降至3.38(差值95%CI -5.37至-1.38,Cohen's d=2.40,p=0.005)。
  • 在ESS-度普利尤单抗亚组分析中,联合组息肉负荷从4.85降至0.00,对照组从4.88降至3.50(差值95%CI -5.68至-1.32,Cohen's d=-1.69,p=0.009)。

临床怎么用

  • 原文未据此给出推荐;作者结论认为联合手术与生物制剂治疗可显著且持续降低息肉负荷,并指出需更大规模研究进一步验证。

局限性

  • 原文未报告局限性;作者在结论中提出需要更大规模的研究来进一步检验联合治疗的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic rhinosinusitis with nasal polyposis (CRSwNP) is often treated with endoscopic sinus surgery (ESS); however, patients may require revision surgery due to recurrence. To date, no studies have compared outcomes for combined surgery and biologic therapy for CRSwNP compared with biologic therapy alone. METHODS: Retrospective case-control study of CRSwNP patients who underwent ESS while on dupilumab or mepolizumab (ESS-biologic cohort) compared with CRSwNP patients on biologic therapy (biologic-only controls). Cohorts were matched according to indication, aspirin-exacerbated respiratory disease (AERD), sinonasal outcome test-22 (SNOT-22), and total polyp scores. RESULTS: Sixteen patients underwent ESS while on biologic therapy (13 dupilumab and 3 mepolizumab). Sixteen patients were biologic-only controls. There were no significant differences between indication, baseline SNOT-22 scores, polyp scores, and AERD status between cohorts. Patients underwent surgery a median of 33 days after starting biologic therapy. After 12 months of follow-up, the total polyp score for the ESS-biologic cohort decreased from 4.73 to 0.09 compared with a decrease from 5.22 to 3.38 for the biologic-only controls (95% confidence interval [CI] of difference: -5.37 to -1.38, Cohen's d: 2.40, p = 0.005). In the ESS-dupilumab subanalysis, the ESS-dupilumab cohort had a significant reduction in polyp burden from 4.85 to 0.00 compared with 4.88 to 3.50 for the controls (95% CI of difference: -5.68 to -1.32, Cohen's d: -1.69, p = 0.009). CONCLUSION: In CRSwNP patients, combined ESS and biologic therapy results in a significant and sustained decrease in polyp burden compared with biologic therapy alone. Larger studies are warranted to further examine the impact of combined therapy.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Garvey E, Naimi B, Duffy A, et al. Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP). Int Forum Allergy Rhinol. 2023. PMID: 37506043. doi:10.1002/alr.23246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。